894 filings
Page 2 of 45
ARS
bcha 6rjc6z9sn
12 Apr 24
Annual report to shareholders
4:29pm
D
em0shikb
26 Mar 24
$7.00 mm in equity / options, sold $7.00 mm, 17 investors
5:02pm
8-K
5nm32
26 Mar 24
Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
7:48am
8-K
6tsc n41mp
19 Mar 24
Delcath Systems Announces $7 Million Private Placement
4:31pm
8-K
1ipy28
19 Mar 24
Delcath Systems Appoints Martha S. Rook as Chief Operating Officer
8:00am
8-K
54krr38
14 Feb 24
Departure of Directors or Certain Officers
4:03pm
8-K
6tcifge8n
31 Jan 24
Other Events
4:03pm
8-K
8974h
8 Jan 24
Regulation FD Disclosure
6:10am
S-8
fk77xoa8 cjy
15 Dec 23
Registration of securities for employees
5:22pm
8-K
ts94ymhf
13 Nov 23
Delcath Systems Reports Third Quarter 2023 Results and Provides Business Update
4:10pm
8-K
2ago3rj nrs5gk
6 Sep 23
Regulation FD Disclosure
4:32pm
424B3
2h55p3y
1 Sep 23
Prospectus supplement
4:01pm
8-K
e0m4nelv9 3ovg0pzemg
15 Aug 23
HEPZATO KIT is the only FDA approved liver-directed therapy to treat metastatic uveal melanoma
6:57am
8-K
i2m z55zkj5
9 Aug 23
Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update
5:23pm
8-K
rm2jcolbx92ikdjj
4 Aug 23
Regulation FD Disclosure
5:30pm
EFFECT
74tkdaq
29 Jun 23
Notice of effectiveness
12:15am